Madrid, 22nd of May 2020

Conference Room – Real Jardín Botánico

Plaza de Murillo, 2

Juan Muñoz Sánchez

Departamento de Derecho Penal, Universidad de Málaga

Speech at 09:45

Manuel Guzmán Pastor

Departamento de Bioquímica y Biología Molecular, Universidad Complutense de Madrid; Spanish Observatory of Medicinal Cannabis, Spain


Manuel Guzmán is a Full Professor of Biochemistry and Molecular Biology at Madrid Complutense University. His PhD and postdoctoral research focused on the regulation of lipid metabolism. During the last 20 years he has been mostly involved in the study of the mechanism of cannabinoid receptor action.

This work has allowed to characterize
new effects and signaling pathways evoked by cannabinoids, as well as putting forward
new physiopathological implications derived from them.

He is an Academic Member of The Spanish Royal Academy of Pharmacy, as well as a member of the Board of Directors of the International Association for Cannabinoid Medicines (IACM). He has published 150 scientific articles and 7 patents, and has supervised 21 PhD theses.

Speech at 10:00

Carola Perez

Spanish Observatory of Medicinal Cannabis

Speech at 10:00

Ethan Russo

MD Founder/CEO of CannabisResearch.org

Speech at 10:10

Roger Pertwee

Institute of Medical Sciences, University of Aberdeen, Scotland, UK

Speech at 10:30

Livio Luongo

Department of Experimental Medicine – Division of Pharmacology, University of Caserta “Luigi Vanvitelli”, Italy

Speech at 10:50

Carlos Goicoechea García

Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Spain

Speech at 11:25

Cristina Sánchez García

Departamento de Bioquímica y Biología Molecular, Universidad Complutense de Madrid, Spain

Speech at 11:45

Eduardo Muñoz Blanco

Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Spain


Doctor in Medicine and Surgery from the University of Córdoba (1986). He made his first postdoctoral stay at Tufts University (Boston, 1987-90) investigating the differential regulation of cytokines in Th1 and Th2 cells. Later, he carried out a second postdoctoral stay at the Pasteur Institute (Paris, 1992-94) studying the regulation of NF-kB by the Tax protein of HTLV- 1.

He is currently Professor of Immunology at the University of Córdoba and director of the BIO304 group of the PAIDI with a score of 26 points (out of 30) in the last year evaluated (2018) by the Andalusian Evaluation Agency.

Since 2012 he also directs the IMIBIC
Inflammation and Cancer group (GC04), a mixed group of basic and clinical researchers.

He has directed 19 doctoral theses (four extraordinary prizes) and his main lines of research are focused on the development of new cannabinoid derivatives with potential application in
chronic and degenerative inflammatory.

Some of these studies have resulted in the discovery of a clinical candidates currently under development with orphan drug status in EU and USA (the cannabinoaminoquinones VCE-004.8 and VCE-003.2). Moreover VCE-004.8 is the API of EHP-101 that has completed a Phase I clinical study (clinicaltrial.gov: NCT03745001) and initiation of Phase II studies in SSc and MS patients are being planned early in 2020.

He is the author of more than 225 scientific articles in international journals, book chapters and patents. He belongs to the editorial board of several scientific journals and is founder of the companies VivaCell Biotechnology (2003) and Glactone Pharma AB (2012), and InnoHealth Group S.L. (2015)

Speech at 12:05

José Javier Fernández Ruiz

Departamento de Bioquímica y Biología Molecular, Universidad Complutense de Madrid


Javier Fernández-Ruiz is a PhD in Biochemistry obtained in 1986 in the Complutense University, Madrid, Spain.

He is currently Full Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine, in such university.

Together with his teaching activities in the areas of Neurochemistry and Neurobiology, both in Degree and Master, he has been working during the last 38 years in different diseases of the Central Nervous System, having authored 236 research articles and 44 review articles in international journals. Also 42 chapters in national and international books and 6 international patents. He has given lectures at different national and international universities and research centers, as well as numerous presentations at national and international congresses.

He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University, and also at two cooperative networks of excellence research in Spain: CIBERNED and IRYCIS.

The main activity of this group is the study of the therapeutic potential of cannabinoids in several neurological diseases, mainly
neurodegenerative, activity addressed to the design, synthesis and biological characterization of novel cannabinoids with neuroprotective profile, and to test their therapeutic efficacy at preclinical and clinical levels. They have also conducted research addressed to explore the contribution of endocannabinoid
dysregulations in the pathogenesis of neurodegenerative disorders.

They are collaborating with several national and international groups, and five pharmaceutical companies: GW Pharma, Emerald Health Pharmaceuticals, Emerald Health Biotechnology Spain, Symrise and Roche. He has participated in numerous research projects, acting as PI in many of them, including 7 research contracts with pharma companies.

He has been a member, representing the UCM, in the IRYCIS Governor Committee (2011- 2017), and is currently a member in the Scientific Advisor Committee of the pharma companies Emerald Health Biotechnology-Spain and Linneo Health SL, and a member of the Editorial Board in the British Journal of Pharmacology.

He has been President of the International Cannabinoid Research Society (ICRS) (2002- 2003) and member of its Executive Committee (2001-2004), as well as a founding member of the Spanish Cannabinoid Research Society (SEIC) and member of its Executive Committee (2000-2013) serving as President during 2007-2011.

Speech at 14:30

Vittorio A. Guardamagna

Palliative Care and Pain Therapy Unit, European Institute of Oncology, Milan, Italy

Speech at 14:40

Ana Maria Zuniga Guerrero

Palliative Care and Pain Therapy Unit, European Institute of Oncology, Milan, Italy

Speech at 15:00

Pasquale Striano

University of Genova,
‘G. Gaslini’ Institute, Italy

Speech at 15:30

Pere Gascon

Hospital Clínic Barcelona, Spain

Speech at 15:40


Real Jardin Botánico
Plaza de Murillo 2, 28014 Madrid, Spain


Plaza Murillo 2
22 May 2020, From 9h to 16h.